Recent studies have shown that gene therapy with type I interferon ( IFN ) in an adenovirus vector is a powerful tool to suppress the growth of human tumors transplanted in immune -deficient mice. However, in these studies the host immune -mediated effects, which may be important in mediating the long -term control of tumor growth by these cytokines, was not studied. In this paper, we evaluate the antitumor efficacy of different adenoviral vectors containing mouse IFN -genes ( i.e., a first -generation replicationdefective vector containing IFN -1 and two different second -generation vectors containing IFN -2 ) in immunocompetent DBA / 2 mice transplanted with highly metastatic Friend leukemic cells resistant in vitro to type I IFN. We found that injection of all the different adenovirus vectors containing mouse IFN -genes resulted in a marked antitumor response in mice transplanted either subcutaneously or intravenously with IFN -resistant Friend leukemic cells compared to tumor -bearing animals inoculated with a control vector. Tumor growth inhibition after injection of IFN ± adenovirus vectors was associated with a prolonged presence of high IFN levels in the sera of the injected mice. Suppression of metastatic tumor growth was also observed after a single injection of the IFN ± adenovirus recombinant vectors, whereas a comparable antitumor response generally required several injections of high doses of IFN. Altogether, these results demonstrate that IFN ± adenoviral vectors can efficiently inhibit metastatic tumor growth by hostmediated mechanisms and suggest that adenovirus -mediated IFN -gene therapy may represent an attractive alternative to the conventional clinical use of this cytokine, which generally requires multiple injections of high IFN doses for a prolonged period of time.
T ype I interferons (IFNs ) are cytokines endowed with multiple biological functions, 1 ± 3 including antitumor and antiviral activities. IFNs (especially IFN -) are among the most used cytokines in human subjects. 1, 3 IFN -is used worldwide for the treatment of more that 14 types of cancer, including some hematological malignancies ( hairy cell leukemia, chronic myeloid leukemia, some B -and T-cell lymphomas ) and certain solid tumors, such as melanoma, renal carcinoma, and Kaposi's sarcoma. However, it is unclear whether the current clinical use of IFN represents the most effective strategy for achieving optimal responses in patients with these cytokines or whether new delivery strategies or treatment modalities can result in more pronounced and selective antitumor effects. Pharmacokinetic studies have indicated that IFNs exhibit an extremely short half -life in the blood system after parenteral administration, 2 suggesting that the poor response observed in some clinical trials with patients with cancer can be due to an insufficient delivery of the cytokine to the correct target site. In particular, one of the critical issue in the clinical use of IFN is the adverse side effects often observed in patients, because repeated injections of high doses of cytokines are apparently needed to achieve an antitumor response. 4 Thus, alternative strategies of delivery of this clinically useful cytokine are urgently needed. 4 Over the last decade progress in the development of gene transfer strategies has opened new perspectives for gene therapy of some human diseases, including cancer. 5 The transfer of specific genes, particularly suicide genes, into tumor cells may result not only in the suppression of the tumor phenotype, but also in a bystander effect on both tumor and host cells, resulting in tumor rejection. 6 In particular, cytokine gene transfer into tumor cells has been regarded as a potentially useful approach for the treatment of some human malignancies. 5, 6 Most strategies of cytokine gene transfer have been based on the insertion of cytokine genes into tumor cells to generate more effective cell -based cancer vaccines. 7 Recently, several studies have also shown the potential of in vivo gene transfer by direct injection of various types of vectors ( reviewed in Ref. 5 ) . Although several studies have been published on the in vivo behavior of genetically modified tumor cells expressing IFN -by our group 8 ± 16 as well as by others, 17 ± 20 only a few reports are available on the response of tumors to the direct injection of viral vectors or plasmids containing the IFN -genes. 21 ± 23 Delivery of IFN as a gene may represent an attractive alternative cancer treatment modality to enhance efficacy and /or reduce systemic toxicity, because treatment with exogenous cytokines generally requires multiple injections. 4,24 ± 26 Adenoviruses have been used successfully to deliver a variety of therapeutic genes 22,23,27 ± 43 and may exhibit some advantages for in vivo gene transfer strategies. Recently, adenovirus -mediated type I IFN gene transfer has been show to be a powerful approach for inducing the suppression of human tumor growth in immune-deficient mice. 22, 23, 28 However, tumor models represented by immune -deficient mice transplanted with human tumor may exhibit limitations for predicting a human antitumor response to type I IFN. In fact, previous studies have emphasized the importance of the interactions of type I IFN with an intact immune system in mediating a long -lasting antitumor response to these cytokines, 24 ± 26 and recent results suggest that T lymphocytes and other immune cells play an essential role in the antitumor action of IFN (reviewed in Ref. 44 ). In the present study, we have investigated the antitumor response in immune -competent tumor-bearing mice after inoculation of replication -defective adenovirus vectors containing mouse IFN -genes, in comparison with the repeated treatment with exogenous IFNs. In selecting the tumor system for this set of studies, we have chosen the model of DBA /2 mice transplanted with IFN -resistant Friend leukemia cells (FLC ), because this tumor had been extensively characterized for the antitumor response to various treatment regimens with type I IFN 24 ± 26 and allowed us to specifically evaluate the importance of the host immune mechanisms. We report that injection of different adenovirus vectors containing mouse IFNgenes results in a marked antitumor response in mice transplanted with highly metastatic IFN -resistant FLC. This is associated with a prolonged in vivo production of IFN after vector inoculation. Suppression of metastasis was also observed after a single injection of the adenovirus vectors, whereas a comparable antitumor response generally requires several injections of high doses of IFN, suggesting that adenovirus -mediated IFNgene transfer may represent an attractive alternative to the conventional clinical use of this cytokine in patients with cancer.
MATERIALS AND METHODS

Mice
Male DBA / 2, 6 ±7 weeks old, were purchased from Charles River Breeding Laboratories ( Calco, Italy ).
Tumor cells
3Cl -8, an IFN -/ ± resistant clone of FLC passaged in vitro, was originally obtained from Dr. E. Affabris ( Rome ). 45 The cells were subsequently passaged in vivo by weekly intraperitoneal ( i.p. ) injections into DBA /2 mice. These in vivo ±passaged 3Cl -8 FLC were highly metastatic for the liver and the spleen. 46 
IFN titration
IFN was titrated on L929 cells as previously described. 47 IFN titers are expressed in international units.
Morphological analysis
For histologic evaluation, tissues were fixed in 10% neutral buffered formalin, embedded in paraffin, sectioned at 4 m, and stained with hematoxylin ±eosin or Giemsa.
Titration of antibodies to FLC in sera of FLC-injected DBA / 2 mice Titration of antibodies to 3Cl -8 FLC was performed by a radio -immunoassay, using a 125 I -labeled antimouse immunoglobulin, as described in detail elsewhere. 26 Hybrid IFN 1/8 expression and purification
The coding region of the hybrid IFN8(1±62) /1(63± 92 ) /8 (93 ±166) 48, 49 was expressed in yeast ( Saccharomyces cerevisiae ) under the control of the inducible promoter of the yeast acid phosphatase (PHO5) . The expression cassette comprised the regulated PHO5 promoter, the coding sequence of the IFN hybrid and the PHO5 transcription terminator. The IFN expression cassette was cloned into the multicopy yeast ±Escherichia coli shuttle vector pDP34. 50 The resultant plasmid was used to transform S. cerevisiae strain H449 (MATa; prb1; cps1; leu2 -3; 112; ura3Á5; cir8) . A yeast transformant harboring the IFN expression plasmid was grown in a 30 -liter fermenter under inducing conditions. 51 After growth, cells were harvested and resuspended in 3 liters of 0.1 M phosphate buffer containing 0.5 M NaCl, at pH 7.8. Cells were broken by mechanical forces (Dyno Mill ) and centrifuged at 12,000Âg for 20 minutes. The IFN titer was 350 mg / L. IFN was purified using metal ± chelate affinity chromatography ( Chelating Sepharose Fast Flow, Pharmacia , Uppsala, Sweden) loaded with copper ions. After loading the protein solution, the gel was washed with 10 mM Tris ± HCl buffer at pH 7.6. The protein was desorbed from the gel with 2 mM NH 4 Cl in 25 mM Tris ±HCl buffer at pH 7.6. After dialysis against 20 mM Tris ± HCl buffer at pH 8.0, IFN was further purified by anion -exchange chromatography in two successive runs on a Mono Q HR 16 /10 column ( Pharmacia ) using an NaCl gradient (0 ± 0.3 M) in 20 mM Tris ±HCl buffer at pH 8.0. The protein was concentrated by ultrafiltration and further purified by gel filtration chromatography (Superdex -75, Pharmacia ) using 60 mM Na /phosphate buffer at pH 7.6. The purified IFN ( > 99% purity ) was then stored at À 708C Cancer Gene Therapy, Vol 8, No 1, 2001 in 60 mM Na /phosphate buffer containing 0.2 M mannitol. All purification steps were performed at 48C. The biological activity of the recombinant hybrid IFN was measured by a cytopathic protection assay in 96-well microtiter plates, as previously described. 52 The specific activity was 2.12Â10 8 U /mg of protein.
Adenoviral vectors
The Ad -CMVmIFN1 is a ÁE1 /ÁE3 -deleted vector containing the mIFN1 gene under the transcriptional control of a CMV immediate early promoter. A mIFN1 gene was cloned, as a BamHI fragment, downstream of the CMV promoter in pcDNA3.1/ Zeo + ( Invitrogen, Groningen, Netherlands). The CMVmIFN1 expression cassette was excised using BglII /EcoRI enzymes and then subcloned in BamHI /EcoRI pÁE1sp1A ( Microbix Biosystems, Toronto, Canada ), thus generating pÁE1sp1A ± CMVmIFN1. The Ad -CMVmIFN1 was obtained by homologous recombination between pÁE1sp1A ± CMVmIFN1 and a shuttle plasmid pBHG10 ( Microbix Byosystems ) . They were cotransfected by calcium phosphate precipitation technique into E1 -expressing 293 cell line, which is permissive for replication of E1 -defective adenoviruses. The transfected 293 cells were overlaid with agar to prevent virus spread. Plaques in the cell monolayer resulting from the cytopathic effect of the virus were recovered. Single plaques were used to infect 293 cells and viral DNA from infected cells was analyzed by restriction analysis using HindIII.
Single plaques containing the recombinant adenovirus were amplified on 293 cells and then purified by CsCl density. The titer of Ad -CMVmIFN1 was measured as plaqueforming units ( pfu ) on 293 cells by standard plaque assay.
The construction of Ad -TTRmIFN2 and HDTTRmIFN2 has been described elsewhere. 53 AdTTRmIFN2 is a ÁE1 /ÁE3 -deleted vector containing the mIFN2 gene under the control of the liver-specific transthyretin minimal enhancer and promoter followed by the bovine growth hormone poly -A site. HD -TTRmIFN2 is a helper -dependent adenoviral vector containing the same mIFN2 expression cassette. Ad -TTRmIFN2 was produced in 293 cells and HD -TTRmIFN2 in 293Cre cells. 54 Both adenovirus vectors were purified by CsCl density and physical particles were measured by optical density of DNA. The titer of Ad -TTRmIFN2, measured as pfu, was determined on 911 cells by standard plaque assay. Ad -gal is a first -generation vector that carries the -galactosidase gene under the transcriptional control of a CMV immediate early promoter ( Quantum Biotechnologies, Canada ) . Figure 1 illustrates the different adenovirus vectors used in this study.
Statistical analyses
Data were analyzed by Wilcoxon rank sum test.
RESULTS
Antitumor effects of peritumoral injection of a replication -defective adenovirus vector containing the murine IFN -1 gene in mice bearing metastatic FLC tumors
In a first set of experiments, we evaluated the effects of injection of a replication -defective adenovirus vector containing IFN -1 gene in DBA /2 mice bearing 3-day subcutaneous tumors. As shown in Figure 2 , repeated injection of the IFN -adenovirus vector resulted in a marked antitumor response with respect to the animals treated with a control vector, as evaluated by the survival time. In fact, all mice injected with the control vector had died by day 34, showing massive liver and spleen metastases at autopsy, whereas animals treated with the IFN ±adenovirus vector survived longer and approximately 30% of the mice proved to be tumor-free at the end of the experiment ( day 120 ). In this experiment, serum samples from mice in each group were tested for IFN activity on day 14 (4 days after the injection of adenovirus vectors) . Values ranging from 80 to 160 U /mL of IFN were detected in the sera of mice injected with 
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the IFN ± adenovirus vector, whereas no IFN activity was found in control injected animals ( data not shown) . Notably, the titration of anti -FLC antibodies in the sera revealed that mice injected with the IFN ± adenovirus vector had developed considerable levels of tumorspecific antibodies (titer range: 160 ±640 ) on day 14. In contrast, barely detectable levels of anti -FLC antibodies ( titer <160 ) were observed in the sera of control tumorbearing mice at the same time after FLC injection.
Persistence of in vivo IFN production and antitumor efficacy after a single injection of IFN -± expressing adenoviruses in mice injected intravenously ( i.v. ) with metastatic 3Cl -8 FLC
In the following set of experiments, we evaluated the efficacy of a single injection of various adenovirus vectors containing mouse IFN -genes. We first determined whether a single i.v. injection of IFN -±expressing adenoviruses could result in any detectable IFN production in vivo at different times after inoculation. As shown in Figure 3 , 2 days after the i.v. injection of 10 8 pfu of Ad -CMVmIFN1, high titers of IFN were found in the sera of the injected mice, whereas no detectable IFN activity was found in the sera of mice receiving a similar dose of Ad -TTRmIFN2 and HD -TTRmIFN2. Comparable high levels of IFN were detected in the sera of mice injected i.v. with the all of the mIFN -±expressing adenoviruses at days 7 and 14 after adenovirus administration, with the levels of serum IFN strongly increasing from days 7 to 14. No IFN activity was detected in the sera of control mice.
We then evaluated whether a single i.v. administration of the different mIFN -±expressing adenoviruses could exert a protective effect in counteracting the growth of experimental metastases in syngeneic mice injected i.v. with highly metastatic 3Cl -8 cells. A single i.v. injection of 10 9 pfu of mIFN -± expressing adenoviruses 3 hours after i.v. inoculation of 10
5 ( approximately 10,000 LD 50 ) metastatic 3Cl -8 cells proved to be very effective in inhibiting the growth of experimental metastases, resulting in a marked increase in survival time compared to control Ad -CMVLacZ -or saline -injected mice ( Fig 4) . In all the groups of mice receiving the IFN -± expressing adenoviruses, the increase in survival time was statistically significant compared to control groups of mice. In fact, a 2 -fold increase in survival time was observed in the groups of mice treated with Ad -TTRmIFN2 or AdCMVmIFN1 (days 27 and 21, respectively ) and a 3 -fold increase in HD -TTRmIFN2± treated mice (day 34) , compared to control groups (day 12) (Fig 4 ) . The histological examination, performed 7 days after adenovirus administration, revealed the presence of fewer and smaller metastatic nodules in the liver of mIFNadenovirus vector ±treated mice, compared to control salineor Ad -CMVLacZ ±injected animals ( Fig 5 ) . No significant differences were observed by comparing the morphologic features of the livers of mice injected with the different adenoviral vectors. The evaluation of the number of metastatic foci in the various groups of animals showed that mice injected with either saline or the control vector exhibited a 10-fold higher number of liver metastases than mice treated with the IFN ± adenoviral vectors. Occasionally, the blood vessels of the livers of mice injected with the IFN ± adenoviral vectors showed intravascular accumulation of infiltrating leukocytes (Fig 5, panels C and D ) . The small tumor foci observed in mice treated with the IFN ±adenoviral vectors often showed infiltrating leukocytes within the tumor tissue (not shown ).
High levels of serum IFN were detected in the majority ( 75± 100% ) of the mice sacrificed at 7 days after the i.v. injection of the different mIFN -± expressing adenoviruses, whereas no detectable IFN activity was found in the sera of control mice (Fig 6) . A further increase of serum IFN was observed at 14 days after adenovirus administration in the totality of the mice treated with the mIFN -±expressing adenoviruses ( Fig 6 ) .
Effect of a single i.v. injection of mIFN -± expressing adenoviruses in mice bearing s.c. established metastatic tumor
We next evaluated the therapeutic potential of a single i.v. injection of the different mIFN -± expressing adenoviral injections of exogenous hIFN1/8 ( Fig 7 ) . A significant increase in survival time was observed in all the treatment groups compared to control mice ( Table 1 ) . Moreover, 11± 14% of the mice given a single i.v. injection of AdTTRmIFN2, Ad-CMVmIFN1 or HD -TTRmIFN2 were cured. A similar percentage of cured mice ( 12% ) was also observed when the tumor-bearing mice were repeatedly treated with exogenous hIFN1/8 (Table 1) .
DISCUSSION
Although IFN -is widely used in several human neoplastic diseases, a favorable clinical response is not consistently observed and patient compliance is frequently limited, because repeated injections of high cytokine doses are generally required, resulting in considerable side effects and toxicity. 4 Recent data in animal models have shown that IFN -gene therapy may provide a useful alternative for achieving a more effective and selective antitumor response (reviewed in Ref. 55 ) . The antitumor therapeutic potential of IFN gene transfer into experimental tumors has been evaluated using different strategies, either the use of genetically modified tumor or normal cells or the in vivo delivery of IFN genes via injection of viral vectors or plasmid DNA. Adenovirus-mediated IFN -or IFNintratumoral delivery has been shown to be therapeutically effective in different human tumors transplanted into immune -deficient mice. 27 ± 29 However, because immune mechanisms may play a crucial role in the antitumor response to type I IFN, 24 ± 26 it was important to evaluate the efficacy of IFN ± adenovirus vectors in tumors growing in immune -competent hosts.
To the best of our knowledge, the present study is the first report showing antitumor effects of adenovirus vectors containing IFN -genes in immune -competent mice bearing syngeneic tumors. The highly metastatic FLC tumor model used in this study had been extensively used by our group for studying the mechanisms of antitumor action of type I IFN. 24 ± 26 The fact that the 3Cl8 -FLC clone used in our experiments was totally resistant to the in vitro effects of IFN allowed us to investigate the importance of host -mediated mechanisms in the antitumor effects of these cytokines and the relevant mechanisms involved in suppression of metastatic tumor growth. 24 ± 26 Previous studies had shown that a marked antitumor response is achieved in type I IFN ±treated mice, provided the animals were repeatedly treated daily for several weeks with high doses of IFN. 24 ± 26 In the present study, we have found that two peritumoral injections of a replication-defective adenovirus vector containing the mouse IFN -1 gene resulted in a marked suppression of the metastatic tumor growth and a strong increase in survival time as well as in the cure of approximately 30% of the animals. In this regard, it is worth mentioning that a comparable antitumor response in mice bearing s.c. FLC tumors could only be obtained after daily treatments with high doses of type I IFN for at least 30 days.
In previous studies, we had found that the antitumor effects of type I IFN in mice injected with IFN -resistant 3Cl8 FLC was mediated by multiple host mechanisms depending on the tumor injection site. In particular, we had shown that the generation of antibodies to tumor specific antigens and CD4 + T cells were the essential factors responsible for the suppression of metastatic tumor growth in FLC -injected mice treated with type I IFN. 26 Although in the present study we have not specifically investigated the mechanisms involved in tumor suppression, the finding that tumor-bearing mice injected with the IFN ±adenovirus vector had developed specific antibodies against tumor cells, along with a long -lasting IFN accumulation in the serum, suggests that an interaction of IFN with the immune system is important for the suppression of metastatic tumor growth, similarly to our previous observations in FLC -injected mice daily treated with type I IFN. 26 In this regard, it is worth mentioning that we have recently reported that type I IFN can act as a potent adjuvant for the generation of monocyte -derived dendritic cells endowed with powerful activities in vitro as well as in vivo. 56 In addition to the immune mechanisms, type I IFN can exhibit other important host effects, including those on tumor angiogenesis, which may be relevant for cytokine -induced tumor inhibition, 13, 55 especially in the case of tumors implanted s.c. We envisage that multiple host ( immune and nonimmune ) mechanisms, reminiscent of those induced by multiple IFN injections in this system, are responsible for the IFN ± adenovirus ± mediated tumor suppression.
Notably, a sustained production of IFN was observed after IFN ±adenovirus injection, as evidenced by the presence of serum IFN activity at 4 days after the second vector inoculation. It was of interest, therefore, to evaluate whether even a single i.v. injection of three different adenovirus vectors containing mouse IFN -genes could be effective in preventing metastatic tumor growth in mice injected either i.v. or s.c. with metastatic 3Cl8 -FLC. A single injection of any of the three IFN -adenovirus vectors used in this study resulted in a marked suppression of metastatic tumor growth and enhanced survival compared to control injected mice, without major differences depending on the vector. Although at early times after injection (2 days ) considerable titers of IFN were only detected in the serum of mice injected with the Ad -CMVmu-IFN1 vector, comparable levels of serum IFN activities were found at 1 and 2 weeks after the injection of the different IFN adenoviral vectors. Of interest, the serum IFN titers were consistently higher at 2 weeks than at 1 week, suggesting that in vivo transduction of host cells somehow resulted in an in vivo amplification of IFN production, possibly enhanced by IFN itself. In this regard, it is worth mentioning that we had observed that IFN can induce its own production by macrophages as well as by dendritic cells under in vitro conditions ( our unpublished observations ). The detection of considerably high titers of serum IFN at 2 weeks after a single injection of all the three IFN ± adenovirus vectors appears to be rather remarkable because IFN has a very short half -life when conventionally administered by a systemic route. 2, 4 Previous studies had shown that injection of DBA /2 mice with high numbers of IFN -producing FLC resulted in a 11 In these mice, unusual systemic effects, such as extramedullary hematopoiesis in the liver and increase of myeloid cells in the spleen were noted. This was assumed to be due to the chronic exposure of the host to high levels of IFN. 11 Although previous studies had shown that continuous administration of large amounts of type I IFN to suckling mice can induce systemic effects and toxicity, 57 no systemic effects were observed in adult mice treated daily with the same IFN preparations. Notably, the half -life of type I IFN in the circulation after i.v. or i.p. injection is measured in minutes or a few hours, respectively ( reviewed in Refs.
2,4 ), and we have never detected IFN -/ in the blood 24 hours after inoculation of large amounts of IFN. Of interest, mice injected with IFN ±adenovirus vectors did not apparently show these specific pathologic features, despite the constant interferonemia levels that resembled those observed in animals bearing IFN -producing tumors. 11 Thus, we may argue that injection of IFN ±adenovirus vectors somehow results in a qualitatively different in vivo production of IFN with respect to that occurring in mice bearing IFNproducing tumors. 11 Further studies beyond the scope of this article are required to extensively characterize the host cells producing IFN in vivo after injection of the IFN ± adenovirus vectors.
In mice bearing s.c. FLC tumors, a single i.v. injection of the IFN ± adenovirus vectors induced an antitumor effect comparable to that achieved by daily treatments with high doses of IFN for several weeks (Fig 7 and Table 1 ) . It is interesting that the HD -TTRmIFN was as effective as the first -generation vectors. I.v. injection of this vector, which does not express any adenoviral genes, was shown to induce a weaker inflammation and a stronger activity of IFN responsive genes than first -generation adenovirus vectors ( our unpublished observations) .
In conclusion, our data support the concept that adenovirus -mediated transfer of IFN -genes in vivo can represent a powerful approach for inducing an antitumor response and may result in more acceptable strategies of IFN delivery with respect to the current clinical use of this cytokine in patients with cancer, which normally involves repeated treatments with high cytokine doses for several weeks. 4 In the present study, we have on purpose used tumor cells resistant to the direct effects of type I IFN for fully evaluating the importance of the host -mediated antitumor effects in the response to the injection with IFN -adenovirus vectors. However, spontaneous tumors often are responsive ( even though to a variable extent ) to the direct effects of IFNs. Results obtained in xenograft models represented by immunedeficient mice transplanted with human tumor cells have recently pointed out the remarkable antitumor effect induced by the direct action of human type I IFNs produced in vivo as a result of injections with adenoviral vectors. 27 ± 29 Thus, adenovirus -mediated transfer of IFNgenes at the tumor site appears to represent a valuable strategy for fully exploiting the multiple biologic actions of these unique cytokines capable of both directly affecting the growth of tumor cells and of acting as powerful immune adjuvant for the generation of a longlasting antitumor response.
